This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Long-term Follow-up Study of 113 Patients

Martin Glatz, MD; Marjaneh Golestani, MD; Helmut Kerl, MD; Robert R. Müllegger, MD

Arch Dermatol. 2006;142:862-868.

Objectives  To investigate the kinetics of anti–Borrelia burgdorferi antibodies for a minimum of 1 year after antibiotic therapy in patients with erythema migrans (EM) and to correlate antibody titer kinetics with clinical variables.

Design  Retrospective study of serial anti–B burgdorferi antibodies in correlation to clinical variables.

Setting  University-based hospital.

Patients  One hundred thirteen patients with EM.

Interventions  Pretreatment and a median of 4 consecutive posttreatment serum samples from median follow-up of more than 400 days were simultaneously investigated for anti–B burgdorferi IgG and IgM antibodies. Semiquantitative titers were plotted to identify different groups of antibody kinetics. Individual patients were then stratified to those groups according to their antibody development. A statistical comparison of clinical and therapy-related characteristics among the serologic groups was performed.

Results  Anti–B burgdorferi IgG and IgM antibody titers developed in 3 distinct courses: persistent positivity across follow-up (IgG: 12 patients, 11%; IgM: 14, 12%), persistent negativity (IgG: 63, 56%; IgM: 47, 42%), and decrease of a positive pretreatment titer to a negative titer approximately 5 months after therapy (IgG: 34, 30%; IgM: 49, 43%). Statistics revealed significant correlations only between persistent positive IgG titers and long disease duration or large EM lesions before therapy.

Conclusions  Long duration or large size of EM before therapy correlates with persistence of a positive anti– B burgdorferi IgG antibody titer after therapy. Serologic profiles do not depend on the type or duration of therapy or the clinical course thereafter. Thus, antibody testing in the follow-up of patients with EM is inappropriate for the assessment of therapeutic response.

Author Affiliations: Department of Dermatology, Medical University of Graz, Graz, Austria.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?